Atoz Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Atoz Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Atoz Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.4M Trade | TransData Nexus

Atoz Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $1.4M Total Trade · DGFT Verified

Atoz Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.4M across 3 products in 3 therapeutic categories. Based on 28 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Clindamycin ($650.0K), Aspirin ($400.0K), Spironolactone ($350.0K).

Atoz Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Atoz Pharmaceuticals Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Atoz Pharmaceuticals Private Limited? — Company Overview & Market Position

Atoz Pharmaceuticals Private Limited is a privately held pharmaceutical company incorporated on February 12, 1998, in Ambattur, Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24231TN1998PTC039891. It operates as a non-government, private limited entity, focusing on the manufacturing of pharmaceutical formulations. The authorized share capital is ₹500,000, with a paid-up capital of ₹100,000.

The registered office is located at 1/8, Balaji Nagar West, Opp. Stead Ford Hospital, Thirumullaivoyal, Ambattur, Chennai 53, Tamil Nadu, 600053, India. As of the latest available data, the company employs approximately 60 professionals. The Annual General Meeting (AGM) for the financial year 2023 was held on September 30, 2024, with the balance sheet filed on March 31, 2024.

What Does Atoz Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Clindamycin$650.0K 2Aspirin

Product Portfolio — Top 3 by Export Value

Atoz Pharmaceuticals Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Clindamycin	Antibiotics	$650.0K	13	0.7%	12
2	Aspirin	Analgesics & Antipyretics	$400.0K	8	1.1%	15
3	Spironolactone	Diuretics	$350.0K	7	0.2%	13

Atoz Pharmaceuticals Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $1.4M. The top category is Antibiotics (46.4% of portfolio), followed by Analgesics & Antipyretics (28.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Atoz Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Atoz Pharmaceuticals Private Limited operates manufacturing facilities in Ambattur, Chennai, Tamil Nadu, India. The facilities are equipped to produce a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and specialized manufacturing capabilities are not publicly disclosed.

3Key Leadership

The company's leadership comprises two directors:

Rajakantham Rajiniganth: Appointed as a director on October 3, 2022.

Viswanathan Shanmugasundaram: Serving as a director since October 9, 2015.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Atoz Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Atoz Pharmaceuticals Private Limited's export data indicates shipments to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's total export value is $1.4 million USD, with 28 shipments across three therapeutic categories. The top three exported products are Clindamycin ($650K), Aspirin ($400K), and Spironolactone ($350K). However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly available.

2Emerging Markets

Atoz Pharmaceuticals Private Limited's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, and Southeast Asia. Additionally, there is no publicly available information indicating WHO prequalification or other certifications that would enable access to these markets.

3Geographic Strategy

The company's export portfolio is concentrated in three therapeutic categories: Antibiotics (46.4%), Analgesics & Antipyretics (28.6%), and Diuretics (25.0%). This concentration suggests a focused product strategy. However, the lack of diversification in product offerings may expose the company to risks associated with market fluctuations in these specific therapeutic areas.

Atoz Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Atoz Pharmaceuticals Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data indicates shipments to the United States, but without detailed regulatory filings, it is challenging to assess the company's standing with the FDA.

2WHO & EU GMP

There is no publicly available information confirming whether Atoz Pharmaceuticals Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. These certifications are crucial for market access in various international regions, and the absence of such certifications may limit the company's ability to expand its global footprint.

3CDSCO & Indian Regulatory

Specific details regarding Atoz Pharmaceuticals Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data indicates shipments to various international markets, suggesting compliance with Indian regulatory requirements for export.

Atoz Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Atoz Pharmaceuticals Private Limited operates in the pharmaceutical industry, exporting products such as Clindamycin, Aspirin, and Spironolactone. While specific competitors in these therapeutic categories are not identified, the company faces competition from both domestic and international pharmaceutical manufacturers. The lack of detailed market share data makes it challenging to perform a comprehensive head-to-head analysis.

2Key Differentiators

Atoz Pharmaceuticals Private Limited's focus on specific therapeutic categories—Antibiotics, Analgesics & Antipyretics, and Diuretics—may allow for specialized expertise and product development in these areas. However, the concentration of its product portfolio could also limit its ability to adapt to changing market demands and diversify its revenue streams.

3Strategic Position

The company's export data indicates a focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. There is no publicly available information suggesting a strategic direction towards generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services. The company's future outlook may benefit from exploring diversification strategies to mitigate risks associated with its current product concentration.

Buyer Due Diligence Brief — Evaluating Atoz Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Atoz Pharmaceuticals Private Limited's export data indicates a total export value of $1.4 million USD across 28 shipments, suggesting a consistent export volume. However, the concentration of its product portfolio in three therapeutic categories may impact the company's ability to adapt to changing market demands. The absence of detailed information regarding the company's supply chain and manufacturing processes makes it challenging to fully assess its reliability and consistency as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and product quality:

FDA Facility Registration: Confirm the company's registration status with the FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify if the company holds WHO Good Manufacturing Practice certification, which is essential for market access in various international regions.

Frequently Asked Questions — Atoz Pharmaceuticals Private Limited

How many pharmaceutical products does Atoz Pharmaceuticals Private Limited export from India?

Atoz Pharmaceuticals Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Clindamycin ($650.0K), Aspirin ($400.0K), Spironolactone ($350.0K). Total export value is $1.4M.

What is Atoz Pharmaceuticals Private Limited's total pharmaceutical export value?

Atoz Pharmaceuticals Private Limited's total pharmaceutical export value is $1.4M, based on 28 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Atoz Pharmaceuticals Private Limited cover?

Atoz Pharmaceuticals Private Limited exports across 3 therapeutic categories. The largest are Antibiotics (46.4%, 1 products), Analgesics & Antipyretics (28.6%, 1 products), Diuretics (25.0%, 1 products).

Get Full Atoz Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.